Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study (Arthritis Care and Research, 2018)

(untitled) - Coates, L; Mease, P; Gossec, L; Kirkham, B; Sherif, B; Gaillez, C; Mpofu, S; Jugl, S; Karyekar, C; Gandhi, K